Funding round
CORE Biomedicine raises $21M Series A round
CORE Biomedicine (USA) has raised $21M in a Series A round, announced on July 28, 2026. The company is Develops lineage-based precision oncology therapeutics for cancer treatment. The round was led by UTokyo Innovation Platform Co., Ltd., with participation from Elikon Venture, InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., Root Venture Partners.
CORE Biomedicine raised $21 million Series A to advance novel cancer therapeutics and received an AMED grant to support research and development.
Track every raise, every day
This deal appeared in The Daily Raise, July 28, 2026. Get the next edition in your inbox.
Just raised too?
Turn your funding news into guaranteed media coverage while the momentum lasts.